The Challenge

Transforming Genome-Wide Association Studies into Disease-Causing Genes

In the last decade, a large number of genetic variants associated with human diseases have been identified, mainly through approaches such as Genome-Wide Association Studies (GWAS). However, the majority of the GWAS findings are non-coding genetic variants, leaving a significant gap in our understanding of their functional impact and the underlying genes they affect. The potential of genomics data has not been fully realized, with the drug target still hiding in plain sight.

D2M is uniquely positioned to bridge this gap by integrating GWAS findings with emerging SNP centered multi-omics data. This integration enables us to systematically identify disease-causing gene and consistently develop a broad set of effective therapies by targeting genetically validated pathways.

Our Solution

D2M has built INGENUITI, a genetic-centric, multi-omics, data-driven platform for target-discovery. Leveraging state-of-art techniques of machine learning and bioinformatics algorithms, we deeply analyze integrated disease and functional genomic data. We utilize human genetic variants as “virtual human natural drugs” and employ the Mendelian Randomization procedures as “virtually conducted human clinical trials” to identify disease-causing genes, ensuring the ultimate success of therapeutics development in clinical studies.

A Global Leader in Genetics-Driven Therapeutics

D2M has a team of top industry leaders in genetic-driven target science, bioinformatics and biologics discovery. Our team is dedicated to integrating expertise from various disciplines including bioinformatics, immunology, pharmacology, CMC, and clinical development.

Currently, D2M is focusing on broadening innovative therapies in oncology and immune-inflammatory diseases through genetics-validated targets. We are committed to establishing ourselves as leaders in genetics-driven therapeutics.

We Are Ready

D2M has brought forth a diverse pipeline of innovative therapies, focusing on next-generation immuno-oncology, and severe inflammatory diseases with limited treatment options. Our first asset DM919 has progressed into the clinical stage, marking the beginning of our journey towards bringing pioneering treatments to patients. Additionally, we have multiple first-in-class programs in the pre-clinical discovery and IND-enabling phases, further solidifying our commitment to advancing groundbreaking therapeutics.